Autoinflammatory diseases are driven by dysregulation of the innate immune system rather than adaptive immune responses, leading to recurrent fevers, rashes, and systemic inflammation. Conditions range from monogenic periodic fever syndromes to multifactorial diseases such as adult-onset Still's disease. Interleukin-1 blockade has proven transformative across multiple autoinflammatory phenotypes.
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
Targeting CD19+ B-cells offers a corticosteroid-sparing strategy for IgG4-Related Disease, addressing relapse rates and long-term toxicity.
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
CAR T cell therapy demonstrates promising efficacy in refractory autoimmune diseases, offering a potential new therapeutic avenue for severe cases.
CAR T-Cell Therapy Shows Efficacy in Refractory Autoimmune Disease
CAR T-cell therapy, traditionally for cancer, demonstrates potential in severe autoimmune conditions, offering a new therapeutic avenue.
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Managing hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic and therapeutic challenges.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12